Moteur de recherche d’entreprises européennes
Financement de l’UE (5 998 840 €) : Approche pragmatique de la thérapie cellulaire adoptive (ACT) utilisant des lymphocytes infiltrant la tumeur (TIL) dans des tumeurs solides sélectionnées Hor 01/04/2023 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Approche pragmatique de la thérapie cellulaire adoptive (ACT) utilisant des lymphocytes infiltrant la tumeur (TIL) dans des tumeurs solides sélectionnées
"The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment modality in academic hospitals. To this end, treatment related toxicities, associated to high-dose interleukin 2 (HD-IL-2) required for expansion and activation of TILs will be reduced while maintaining efficacy. This improved tolerability will achieve a better clinical management of patients and enhance their quality of life, both of which represent major barriers for applying this treatment. The objectives of PragmaTIL are: i) To determine whether TIL-ACT using IL-2 analog ANV600 reduces the frequency of Grade ≥3 study-related non-hematological toxicities; ii) To compare the quality of life (QoL) of patients during their hospitalization period, using ANV600 vs HD-IL-2. Also, to compare short and long-term measurements of treatment-related toxicities and QoL co-defined by and for patients and their caregivers; and iii) To develop the health technology assessment (HTA) of TIL-ACT using ANV600, as well as a social return of investment (SROI) analysis. To achieve these objectives, the PragmaTIL project is structured into 6 WP that cover all the requirements to implement the project: WP1) Clinical Trial; WP2) IMPD Coordination, RA and Pharmacovigilance; WP3) Patients as co-researchers and Evaluation of Short- and Long-term PROs; WP4) Health Economics; WP5) SROI, Sustainability and Exploitation; WP6) Scientific Coordination, Project Management, Communication and Dissemination. The global impact of this project will not only reach patients, clinical and translational researchers and policy makers but may help to achieve a better acceptance of these therapies by society at large. This action is part of the Cancer Mission cluster of projects on ""Diagnosis and treatment""."
| Asphalion SL | 168 125 € |
| Banc de Sang i Teixits | 0,00 € |
| BCN Health Economics & Outcomes Research SL | 198 125 € |
| Citoyens et Recherche | 169 375 € |
| Fundacion Bancaria Caixa D Estalvis i Pensions de Barcelona La Caixa | 111 719 € |
| Fundacio Privada Institut D'Investigacio Oncologica de Vall-Hebron (Vhio) | 1 103 574 € |
| Innovandum Health SL | 88 235 € |
| Institut Gustave Roussy | 219 375 € |
| Medical Research Infrastructure Development AND Health Services Fund BY THE Sheba Medical Center | 912 969 € |
| Region Hovedstaden | 882 781 € |
| Region Stockholm | 912 219 € |
| Stichting HET Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | 912 969 € |
| Unicancer | 319 375 € |
https://cordis.europa.eu/project/id/101104684
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.